New US guidelines may affect how young adults manage ‘bad’ cholesterol - CNN

What the report says

CNN reported that updated U.S. cholesterol treatment guidance could substantially widen the group of adults considered eligible for statins, the common drugs used to lower LDL, or “bad,” cholesterol. Citing a new JAMA analysis, CNN said researchers estimated that about 21.5 million more U.S. adults could qualify under 2026 guidelines from the American Heart Association, the American College of Cardiology and partner medical societies, compared with 2018 recommendations.

The study applied both sets of guidelines to national health survey data from more than 4,300 participants collected from 2017 to 2023, representing about 154 million adults ages 30 to 79 without known cardiovascular disease. Under the new framework, CNN reported, roughly 87.5 million people — nearly 57% of that population — could be eligible for statins for primary prevention, meaning treatment aimed at preventing a first heart attack, stroke or other cardiovascular event.

CNN wellness expert Dr. Leana Wen said the expansion is driven by several changes: risk assessment now covers ages 30 to 79 rather than focusing mainly on ages 40 to 75; thresholds for risk categories are lower; conditions such as advanced chronic kidney disease and HIV carry more weight; and longer-term, 30-year cardiovascular risk is emphasized for many younger adults. The goal is to identify people earlier, since cholesterol-related plaque can build over decades.

CNN emphasized that eligibility does not automatically mean a patient should begin medication. Decisions should be individualized with a clinician, using a lipid panel, medical history and tools such as the American Heart Association’s PREVENT calculator. In uncertain cases, coronary artery calcium scans or additional blood tests may help refine risk and guide whether lifestyle changes, statins or continued monitoring are appropriate.